No Data
US Stock MarketDetailed Quotes
CSTL Castle Biosciences
Watchlist
19.480
-0.300-1.52% Close 11/28 16:00 ET
19.4800.0000.00%
Post 16:02 ET
19.710High19.035Low176.79KVolume
19.610Open19.780Pre Close3.44MTurnover0.68%Turnover RatioLossP/E (TTM)524.22MMarket Cap29.59052wk HighLossP/E (Static)26.91MShares9.26052wk Low1.36P/B504.91MFloat Cap107.690Historical High--Dividend TTM25.92MShs Float9.260Historical Low--Div YieldTTM3.41%Amplitude19.441Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Castle Biosciences Company
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Revenue Breakdown
Business
Unit:USD
2022/12/31
Stock NameRevenueRatio
Dermatologic124.81M91.08%
Non-Dermatologic12.23M8.92%
News
Castle Biosciences(CSTL.US) Officer Sells US$12,018 in Common Stocks
$Castle Biosciences(CSTL.US)$ Officer MAETZOLD DEREK J sold 600 shares of Common Stocks on Nov 24, 2023 at an average price of $20.03 for a total value of $12,018.Source: Announcement What is statemen
Castle Biosciences(CSTL.US) Director Sells US$16,016 in Common Stocks
$Castle Biosciences(CSTL.US)$ Director BRADBURY DANIEL sold 800 shares of Common Stocks on Nov 24, 2023 at an average price of $20.02 for a total value of $16,016.Source: Announcement What is statemen
Castle Biosciences(CSTL.US) Director Sells US$121.33K in Common Stocks
$Castle Biosciences(CSTL.US)$ Director BRADBURY DANIEL sold 6,055 shares of Common Stocks on Nov 20, 21, 2023 at an average price of $20.04 for a total value of $121.33K.Source: Announcement What is s
Comments
On watch
$Castle Biosciences(CSTL.US$ Keeping a close eye to see what comes out of this? (. New Data Highlights Clinical Utility and Performance of Castle Biosciences' Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference
Businesswire· 4 mins ago
Businesswire· 4 mins ago
The insider's willingness to buy shares above the current price suggests their confidence in the company's future and indicates that they viewed the stock as good value, even at a higher price.
NEWS!
$Castle Biosciences(CSTL.US$ DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--